Merck & Co (MRK)

$125.52 0.15 (0.12%)

9:30 EDT MRK Stock Quote Delayed 30 Minutes

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

By Chandler Capital, InvestorPlace Contributor Apr 17, 2024

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

3 Dow Stocks to Buy Now: Q2 Edition

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

Volume:

Previous Close -

Market Cap 317.74B

PE Ratio 896.57

EPS 0.14

Volume (Avg. Vol.) 1,192

Day's Range $125.52 - $125.52

52-Week Range $99.14 - $133.10

Dividend & Yield $2.92 (2.33%)

MRK Stock Predictions, Articles, and Merck & Co News

From InvestorPlace
From the Web

The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

By Michael Que, InvestorPlace Contributor Apr 7, 2024

Our economy is on the up and up, and investing is a must,. Let's review the most undervalued S&P 500 stocks to buy in April.

3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List

By Faizan Farooque, InvestorPlace Contributor Mar 29, 2024

UNH's stellar year, ABT's dividend aristocracy, MRK's AI leap: Unpacking the best strong buy healthcare stocks for 2024.

7 Dow Darlings for Investors to Buy for March Market Madness

By Alex Sirois, InvestorPlace Contributor Mar 13, 2024

These 7 Dow stocks are better positioned than the other 23 within the index making them strong buy considerations.

SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster

By Rich Duprey, InvestorPlace Contributor Mar 13, 2024

With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.

The Top 3 Dow Stocks to Buy in March 2024

By Charles Munyi, InvestorPlace Contributor Mar 4, 2024

Play defense with these top Dow stocks to buy as the market takes a breather from the 20% rally that started in November 2023.

7 Timeless Stocks to Invest in for 2024

By Faisal Humayun, InvestorPlace Contributor Mar 1, 2024

These are attractive timeless stocks to buy as they represent quality companies with the potential to deliver healthy total returns.

3 Long-Term Winners from Charles Schwab’s Top Picks

By Stavros Tousios, InvestorPlace Contributor Feb 27, 2024

Explore the growth and resilience of long-term stocks Microsoft, Merck and Veralto in the latest Charles Schwab stocks portfolio update.

3 Top Pharma Stocks for Investors Betting on a Biotech Boom

By Rick Orford, InvestorPlace Contributor Feb 26, 2024

Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.

3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report

By Stavros Tousios, InvestorPlace Contributor Feb 15, 2024

Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.

3 Pharma Stocks to Sell in February Before They Crash and Burn

By Ian Bezek, InvestorPlace Contributor Feb 2, 2024

The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn.

Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?

By William White, InvestorPlace Writer Jan 24, 2024

Evaxion Biotech stock is climbing higher on Wednesday alongside news of Merck acquiring shares of EVAX for an 11.4% stake in the company.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jan 24, 2024

It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.

The 3 Best Dividend Growth Stocks to Buy in January 2024

By Faisal Humayun, InvestorPlace Contributor Jan 17, 2024

These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility.

The 3 Best Blue-Chip Stocks to Buy in January 2024

By Charles Munyi, InvestorPlace Contributor Jan 10, 2024

With a history of consistent shareholder returns, the best blue-chip stocks will reward patient investors in 2024.

Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?

By William White, InvestorPlace Writer Jan 8, 2024

Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share.

January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump

By Yiannis Zourmpanos, InvestorPlace Contributor Dec 24, 2023

Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump.

7 Best Dow Jones Stocks to Buy for Conservative Investors

By Josh Enomoto, InvestorPlace Contributor Dec 21, 2023

With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative…

Why Is Moderna (MRNA) Stock Up 11% Today?

By William White, InvestorPlace Writer Dec 14, 2023

Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.

Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?

By William White, InvestorPlace Writer Dec 12, 2023

C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.

Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times

By Josh Enomoto, InvestorPlace Contributor Nov 23, 2023

At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing…

Merck & Co (MRK)

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

3 Dow Stocks to Buy Now: Q2 Edition

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Merck & Co (MRK)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

MRK Stock Predictions, Articles, and Merck & Co News

Subscriber Sign in